Anti-Human PD-1 Reference Antibody (Cetrelimab, RUO) (HS870046)

Name: Anti-Human PD-1 Reference Antibody (Cetrelimab, RUO)
Brand: abinScience
SKU: HS870046
Price: 176 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HS870046
Description	Cetrelimab (HS870046) is a research-grade recombinant antibody targeting CD1. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG4-kappa
Expression system	Mammalian cells
Clonality	Monoclonal
Target	Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279
Endotoxin level	< 10 EU/mg
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	Q15116
Form	Liquid
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	JNJ-63723283, 2050478-92-5
Background	Programmed cell death protein 1 (CD279/PD-1) is a ~31 kDa protein. Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self. Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2. Following T-cell receptor (TCR) engagement, PDCD1 associates with TCR-CD3 in the immunological synapse and directly inhibits T-cell activation. Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta. CD279 is the therapeutic target of pembrolizumab (Keytruda) and nivolumab (Opdivo). 1. Fife, BT. et al. (2011) Annals of the New York Academy of Sciences 1217, 45-59. PMID: 21276005 2. Bardhan, K. et al. (2019) Scientific reports 9, 17252. PMID: 31754127 3. Patsoukis, N. et al. (2020) Communications biology 3, 128. PMID: 32184441 4. Xiao, X. et al. (2023) Nature communications 14, 2859. PMID: 37208329 5. Zak, KM. et al. (2015) Structure (London, England : 1993) 23, 2341-2348. PMID: 26602187
Note	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG4 (S228P) Recombinant Isotype Control Antibody (13R4) (HP298207) Human IgG4 (S228P) Recombinant Isotype Control Antibody (HyHEL-10) (HP298307) Human IgG4 (S228P) Recombinant Isotype Control Antibody (SAA0184) (HP298107)